Literature DB >> 19356483

Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia.

Benedetta Leonardi1, Renee Margossian, Steven D Colan, Andrew J Powell.   

Abstract

OBJECTIVES: We sought to evaluate whether echocardiographic diastolic function indices correlate with myocardial iron and systolic function in patients with transfusion-dependent thalassemia (TDT) who are at risk for cardiomyopathy.
BACKGROUND: In thalassemia syndromes, there is an important clinical need to risk stratify patients for the development of iron-overload cardiomyopathy so that chelation therapy can be adjusted and cardiac morbidity averted. This purpose may be served by measuring the magnetic resonance imaging (MRI)-derived parameter T2*, which varies inversely with tissue iron concentration but has limited availability. As diastolic dysfunction may precede systolic dysfunction, we sought to directly compare more readily available echocardiographic indices of diastolic function to myocardial T2* and ejection fraction (EF).
METHODS: We identified 47 paired echocardiography and MRI examinations in 24 patients with TDT. Echocardiographic measurements of transmitral flow velocities (E, A), tissue Doppler velocities (E'), and left ventricular volume and EF were compared with MRI measurements of myocardial T2*, ventricular volume, and EF.
RESULTS: All patients had a restrictive filling pattern (E/A >or=1.5 and deceleration time <140 ms) and normal relaxation. There was no significant correlation between E/E' or the Tei index versus EF. Although E/A and E' had statistically significant correlations with EF, the relationships were weak with all correlation coefficients <0.52. The parameters E/A, E', E/E', and the Tei index did not significantly correlate with myocardial iron concentration as assessed by MRI T2*. Increased myocardial iron as measured by T2* was strongly associated with lower left ventricular EF, with a T2* <9 ms having a sensitivity of 100% and specificity of 89% for MRI EF <50%.
CONCLUSIONS: In patients with TDT, echocardiographic diastolic function parameters correlated poorly with EF and myocardial T2* and were thus not well-suited for risk stratification. Myocardial T2* had a strong relationship with EF and appears to be a promising approach for predicting the development of heart failure and for iron chelator dose adjustment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19356483     DOI: 10.1016/j.jcmg.2008.04.005

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  28 in total

1.  Detection of myocardial iron overload by two-dimensional speckle tracking in patients with beta-thalassaemia major: a combined echocardiographic and T2* segmental CMR study.

Authors:  Fausto Pizzino; Antonella Meloni; Anna Terrizzi; Tommaso Casini; Anna Spasiano; Carlo Cosmi; Massimo Allò; Concetta Zito; Scipione Carerj; Giovanni Donato Aquaro; Gianluca Di Bella; Alessia Pepe
Journal:  Int J Cardiovasc Imaging       Date:  2017-08-02       Impact factor: 2.357

2.  The reproducibility and absolute values of echocardiographic measurements of left ventricular size and function in children are algorithm dependent.

Authors:  Renee Margossian; Shan Chen; Lynn A Sleeper; Lloyd Y Tani; Girish Shirali; Fraser Golding; Elif Seda Selamet Tierney; Karen Altmann; Michael J Campbell; Anita Szwast; Angela Sharkey; Elizabeth Radojewski; Steven D Colan
Journal:  J Am Soc Echocardiogr       Date:  2015-02-27       Impact factor: 5.251

Review 3.  Dilated cardiomyopathy with conduction disease and arrhythmia.

Authors:  Neal K Lakdawala; Michael M Givertz
Journal:  Circulation       Date:  2010-08-03       Impact factor: 29.690

4.  Improvements in cardiac function detected using echocardiography in patients with hereditary haemochromatosis.

Authors:  Danielle Byrne; John Patrick Walsh; Caroline Daly; Susan McKiernan; Suzanne Norris; Ross T Murphy; Gerard King
Journal:  Ir J Med Sci       Date:  2019-05-20       Impact factor: 1.568

Review 5.  Advances in MRI Applications to Diagnose and Manage Cardiomyopathies.

Authors:  Ramya Vajapey; Brendan Eck; Wilson Tang; Deborah H Kwon
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

6.  On T2* magnetic resonance and cardiac iron.

Authors:  John-Paul Carpenter; Taigang He; Paul Kirk; Michael Roughton; Lisa J Anderson; Sofia V de Noronha; Mary N Sheppard; John B Porter; J Malcolm Walker; John C Wood; Renzo Galanello; Gianluca Forni; Gualtiero Catani; Gildo Matta; Suthat Fucharoen; Adam Fleming; Michael J House; Greg Black; David N Firmin; Timothy G St Pierre; Dudley J Pennell
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

7.  Evaluation of tissue doppler echocardiography and T2* magnetic resonance imaging in iron load of patients with thalassemia major.

Authors:  Mehrdad Saravi; Ahmad Tamadoni; Rozita Jalalian; Hassan Mahmoodi-Nesheli; Mosatafa Hojati; Saeed Ramezani
Journal:  Caspian J Intern Med       Date:  2013

8.  Early detection of ventricular dysfunction by tissue Doppler echocardiography related to cardiac iron overload in patients with thalassemia.

Authors:  Suchaya Silvilairat; Pimlak Charoenkwan; Suwit Saekho; Adisak Tantiworawit; Somdet Srichairatanakool
Journal:  Int J Cardiovasc Imaging       Date:  2020-07-29       Impact factor: 2.357

9.  Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition.

Authors:  Jane S Hankins; Mary Beth McCarville; Claudia M Hillenbrand; Ralf B Loeffler; Russell E Ware; Ruitian Song; Matthew P Smeltzer; Vijaya Joshi
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

Review 10.  Transplantation in patients with iron overload: is there a place for magnetic resonance imaging? : Transplantation in iron overload.

Authors:  Sophie Mavrogeni; Genovefa Kolovou; Boris Bigalke; Angelos Rigopoulos; Michel Noutsias; Stamatis Adamopoulos
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.